Neuropace Inc (NPCE) Q1 2026 Earnings Call Transcript

Why It Matters

The results demonstrate NeuroPace’s ability to scale its high‑margin RNS platform, generate cash flow, and position for a potentially transformative indication expansion and AI‑driven product suite.

Key Takeaways

• Revenue $26.6M, 24% YoY growth.
• RNS system drives 26% sales increase.
• Positive adjusted EBITDA $0.9M, cash generation.
• FDA PMA supplement for IGE shows 77% seizure reduction.
• AI SeizureID and remote care slated for 2026 launch.

Pulse Analysis

NeuroPace’s latest earnings underscore a maturing business model anchored by its responsive neurostimulation (RNS) system. By expanding adoption in level‑four epilepsy centers and extending community‑access pathways, the company achieved double‑digit revenue growth while pushing gross margins above 77 percent. This operating leverage, combined with a second consecutive quarter of positive adjusted EBITDA, signals a clear trajectory toward cash‑flow breakeven—a milestone that investors closely monitor in the med‑tech space.

Beyond the financials, NeuroPace is leveraging its unique intracranial EEG dataset to launch software innovations that could reshape clinical workflows. The AI‑driven SeizureID tool, slated for a 2026 cloud‑based release, promises to cut physician review time by automatically flagging seizure events, while the Remote Care platform aims to eliminate in‑person programming visits. These digital extensions not only enhance the value proposition of the RNS hardware but also create recurring revenue streams through software‑as‑a‑service offerings, aligning the company with broader trends toward data‑centric medical devices.

Regulatory progress adds another layer of upside potential. The PMA supplement for an idiopathic generalized epilepsy (IGE) indication, supported by a 77 percent median seizure‑rate reduction, positions NeuroPace to address a sizable patient segment lacking device‑based therapies. If the FDA grants approval, the IGE expansion could materially boost future revenue and broaden the addressable market, reinforcing NeuroPace’s competitive moat and long‑term growth outlook.